Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer.

Xin NiePing ZhangJia-Yin GaoGang ChengWei LiuLin Li

Published in: Thoracic cancer (2021)

Toxicity-related dose reduction is common with initiation of afatinib 40 mg/day. Sarcopenic patients might begin treatment with a low dose of afatinib according to tolerance.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
low dose
end stage renal disease
chronic kidney disease
newly diagnosed
peritoneal dialysis
oxidative stress
tyrosine kinase
high dose
prognostic factors
patient reported
replacement therapy
oxide nanoparticles